Paraproteinemic neuropathy

References

• Kyle R A, Therneau T M, Rajkumar S V, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369
   PubMed Web of Science ®Google Scholar
• Kelly J J, Jr, Kyle R A, O'Brien P C, et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31: 1480–1483
   PubMed Web of Science ®Google Scholar
• Yeung K B, Thomas P K, King R H, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 1991; 238: 383–391
   PubMed Web of Science ®Google Scholar
• Gosselin S, Kyle R A, Dyck P J. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991; 30: 54–61
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36: 416–424
   PubMed Web of Science ®Google Scholar
• Eurelings M, Ang C W, Notermans N C, et al. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001; 57: 1909–1912
   PubMed Web of Science ®Google Scholar
• Sadiq S A, Thomas F P, Kilidireas K, et al. The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology 1990; 40: 1067–1072
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mori K, Yamazaki S, et al. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br J Haematol 2003; 123: 600–605
   PubMed Web of Science ®Google Scholar
• Van den Berg L, Hays A P, Nobile-Orazio E, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996; 19: 637–643
   PubMed Web of Science ®Google Scholar
• Quarles R H, Weiss M D. Autoantibodies associated with peripheral neuropathy. Muscle Nerve 1999; 22: 800–822
   PubMed Web of Science ®Google Scholar
• Willison H J, O'Leary C P, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124: 1968–1977
   PubMed Web of Science ®Google Scholar
• Saperstein D S, Katz J S, Amato A A, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311–324
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. Antigenic determinants in IgM paraprotein related neuropathies. Leukemia Lymphoma 2009; 9: 107–109
   Google Scholar
• Verghese J P, Bradley W G, Nemni R, et al. Amyloid neuropathy in multiple myeloma and other plasma cell dyscrasias. A hypothesis of the pathogenesis of amyloid neuropathies. J Neurol Sci 1983; 59: 237–246
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Robles A, Brito-Zeron P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36: 189–196
   PubMed Web of Science ®Google Scholar
• Guillevin L, Karambinis A, Bletry O, et al. Systemic periarteritis nodosa associated with monoclonal gammapathy. 4 cases. Sem Hop 1984; 60: 1325–1327
   PubMedGoogle Scholar
• Kelly J J, Jr, Kyle R A, Miles J M, et al. The spectrum of peripheral neuropathy in myeloma. Neurology 1981; 31: 24–31
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34: 712–720
   PubMed Web of Science ®Google Scholar
• Levine T, Pestronk A, Florence J, et al. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry 2006; 77: 224–228
   PubMed Web of Science ®Google Scholar
• Dellagi K, Dupouey P, Brouet J C, et al. Waldenstrom's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood 1983; 62: 280–285
   PubMed Web of Science ®Google Scholar
• Viala K, Behin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?. J Neurol Neurosurg Psychiatry 2008; 79: 778–782
   PubMed Web of Science ®Google Scholar
• Kelly J J, Jr, Kyle R A, O'Brien P C, et al. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979; 6: 1–7
   PubMed Web of Science ®Google Scholar
• Vital A, Vital C, Julien J, et al. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol (Berl) 1989; 79: 160–167
   PubMed Web of Science ®Google Scholar
• Kelly J J, Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve 1985; 8: 138–150
   PubMed Web of Science ®Google Scholar
• Simmons Z, Bromberg M B, Feldman E L, et al. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 1993; 16: 77–83
   PubMed Web of Science ®Google Scholar
• Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37(Suppl 1)S32–S42
   PubMedGoogle Scholar
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006; 11: 9–19
   PubMed Web of Science ®Google Scholar
• Windebank A J, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27–46
   PubMed Web of Science ®Google Scholar
• Vital A. Paraproteinemic neuropathies. Brain Pathol 2001; 11: 399–407
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A, Witzig T E, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Kyle R A, Therneau T M, Rajkumar S V, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859–866
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005; 18: 673–688
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath D R, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13: 275–282
   PubMed Web of Science ®Google Scholar
• Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007; 69: 573–581
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Fenton R, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 210–216
   PubMedGoogle Scholar
• Zivkovic S A, Delios A, Lacomis D, et al. Small fiber neuropathy associated with multiple myeloma and IgA monoclonal gammopathy. Ann Hematol, in press
   Web of Science ®Google Scholar
• Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285–299
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Lacy M Q, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101: 2496–2506
   PubMed Web of Science ®Google Scholar
• Sung J Y, Kuwabara S, Ogawara K, et al. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 2002; 26: 189–193
   PubMed Web of Science ®Google Scholar
• Mauermann M L, Suarez G A, Sorenson E J, et al. Uniform slowing without conduction block or dispersion in POEMS syndrome. [abstract]. Muscle Nerve 2008; 31: 1369–1370
   Google Scholar
• Turner M R, Warren J D, Jacobs J M, et al. Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma. J Peripher Nerv Syst 2003; 8: 100–107
   PubMed Web of Science ®Google Scholar
• Shibata-Hamaguchi A, Samuraki M, Furui E, et al. B-cell neurolymphomatosis confined to the peripheral nervous system. J Neurol Sci 2007; 260: 249–252
   PubMed Web of Science ®Google Scholar
• Ladha S S, Dyck P J, Spinner R J, et al. Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst 2006; 11: 346–352
   PubMed Web of Science ®Google Scholar
• Naccache L, Thibault S, Hoang-Xuan K, et al. Cerebral lymphoma in a patient with immunoglobulin paraproteinemic polyneuropathy. Muscle Nerve 1997; 20: 122–123
   PubMed Web of Science ®Google Scholar
• Gordon P H, Rowland L P, Younger D S, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997; 48: 1671–1678
   PubMed Web of Science ®Google Scholar
• Beaume A, Brizard A, Dreyfus B, et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 1216–1219
   PubMed Web of Science ®Google Scholar
• Creange A, Theodorou I, Sabourin J C, et al. Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. J Neurol Sci 1996; 137: 35–41
   PubMed Web of Science ®Google Scholar
• Drake W M, Monson J P, Trainer P J, et al. Acute polyneuropathy with chronic lymphocytic leukaemia and paraproteinaemia: response to chlorambucil and prednisolone. J Neurol Neurosurg Psychiatry 1998; 64: 564
   PubMed Web of Science ®Google Scholar
• Gemignani F, Brindani F, Alfieri S, et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 2005; 76: 1410–1414
   PubMed Web of Science ®Google Scholar
• Kyle R A, Rajkumar S V. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma 2005; 6: 102–114
   PubMedGoogle Scholar
• Rajkumar S V, Lacy M Q, Kyle R A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007; 21: 255–265
   PubMed Web of Science ®Google Scholar
• Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86: 3915–3921
   PubMed Web of Science ®Google Scholar
• Eurelings M, Notermans N C, Van de Donk N W, et al. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2001; 24: 1295–1302
   PubMed Web of Science ®Google Scholar
• Kyle R A, Therneau T M, Rajkumar S V, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M A, Therneau T M, et al. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76: 476–487
   PubMed Web of Science ®Google Scholar
• Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994; 117(Part 1)941–947
   PubMed Web of Science ®Google Scholar
• Simmons Z, Albers J W, Bromberg M B, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118(Part 2)359–368
   PubMed Web of Science ®Google Scholar
• Gorson K C, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321–328
   PubMed Web of Science ®Google Scholar
• Katz J S, Saperstein D S, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54: 615–620
   PubMed Web of Science ®Google Scholar
• Gorson K C, Ropper A H, Weinberg D H, et al. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001; 24: 778–786
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2003; 123(Part 4)710–717
   Google Scholar
• Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris) 2002; 158: 979–987
   PubMed Web of Science ®Google Scholar
• Suarez G A, Kelly J J, Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993; 43: 1304–1308
   PubMed Web of Science ®Google Scholar
• Magy L, Chassande B, Maisonobe T, et al. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol 2003; 10: 677–685
   PubMed Web of Science ®Google Scholar
• Gorson K C, Ropper A H. Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 1997; 63: 163–168
   PubMed Web of Science ®Google Scholar
• Simovic D, Gorson K C, Ropper A H. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 1998; 97: 194–200
   PubMed Web of Science ®Google Scholar
• Collins M P, Periquet M I, Mendell J R, et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003; 61: 623–630
   PubMed Web of Science ®Google Scholar
• Periquet M I, Novak V, Collins M P, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999; 53: 1641–1647
   PubMed Web of Science ®Google Scholar
• De Sousa E A, Hays A P, Chin R L, et al. Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. J Neurol Neurosurg Psychiatry 2006; 77: 983–985
   PubMed Web of Science ®Google Scholar
• Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80: 252–262
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, et al. Amyloidosis. Best Pract Res Clin Haematol 2005; 18: 709–727
   PubMed Web of Science ®Google Scholar
• Antoine J C, Baril A, Guettier C, et al. Unusual amyloid polyneuropathy with predominant lumbosacral nerve roots and plexus involvement. Neurology 1991; 41: 206–208
   PubMed Web of Science ®Google Scholar
• Vucic S, Chong P S, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve 2003; 28: 696–702
   PubMed Web of Science ®Google Scholar
• Garces-Sanchez M, Dyck P J, Kyle R A, et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve 2008; 37: 490–495
   PubMed Web of Science ®Google Scholar
• McKechnie S, Yang F, Harper C G, et al. Amyloidoma of a spinal root. Neurology 2003; 61: 834–836
   PubMed Web of Science ®Google Scholar
• Solders G, Nennesmo I, Ernerudh J, et al. Lymphocytes in sural nerve biopsies from patients with plasma cell dyscrasia and polyneuropathy. J Peripher Nerv Syst 1999; 4: 91–98
   PubMed Web of Science ®Google Scholar
• Zivkovic S A, Ascherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand 2007; 115: 432–436
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Latov N, Hays A P, et al. Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 1984; 34: 218–221
   PubMed Web of Science ®Google Scholar
• Pestronk A, Choksi R, Logigian E, et al. Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle Nerve 2003; 27: 188–195
   PubMed Web of Science ®Google Scholar
• Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002; 25: 828–836
   PubMed Web of Science ®Google Scholar
• Connolly A M, Pestronk A, Mehta S, et al. Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of β-tubulin: clinical association with slowly progressive demyelinating polyneuropathy. Neurology 1997; 48: 243–248
   PubMed Web of Science ®Google Scholar
• Hays A P, Latov N, Takatsu M, et al. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 1987; 37: 242–256
   PubMed Web of Science ®Google Scholar
• Trojaborg W, Hays A P, van den Berg L, et al. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995; 18: 730–735
   PubMed Web of Science ®Google Scholar
• Midroni G, Bilbao J M. Dysproteinemic neuropathies. Biopsy diagnosis of peripheral neuropathy, G Midroni, J M Bilbao. Butterworth Heinemann, Boston 1995; 263–282
   Google Scholar
• Vallat J M, Magy L, Richard L, et al. Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy. Muscle Nerve 2008; 38: 904–911
   PubMed Web of Science ®Google Scholar
• King R H, Thomas P K. The occurrence and significance of myelin with unusually large periodicity. Acta Neuropathol 1984; 63: 319–329
   PubMed Web of Science ®Google Scholar
• Vital A, Lagueny A, Julien J, et al. Chronic inflammatory demyelinating polyneuropathy associated with dysglobulinemia: a peripheral nerve biopsy study in 18 cases. Acta Neuropathol 2000; 100: 63–68
   PubMed Web of Science ®Google Scholar
• Authier F J, Bassez G, Payan C, et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003; 60: 808–812
   PubMed Web of Science ®Google Scholar
• Nemni R, Sanvito L, Quattrini A, et al. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry 2003; 74: 1267–1271
   PubMed Web of Science ®Google Scholar
• Vallat J M, Desproges-Gotteron R, Leboutet M J, et al. Cryoglobulinemic neuropathy: a pathological study. Ann Neurol 1980; 8: 179–185
   PubMed Web of Science ®Google Scholar
• Bennett D L, Groves M, Blake J, et al. The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study. J Neurol Neurosurg Psychiatry 2008; 79: 1376–1381
   PubMed Web of Science ®Google Scholar
• Collins M P, Mendell J R, Periquet M I, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000; 55: 636–643
   PubMed Web of Science ®Google Scholar
• Hilton D A, Jacob J, Househam L, et al. Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 2007; 78: 1271–1272
   PubMed Web of Science ®Google Scholar
• Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41: 617–618
   PubMedGoogle Scholar
• Simmons Z, Blaivas M, Aguilera A J, et al. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993; 120: 60–63
   PubMed Web of Science ®Google Scholar
• Lacomis D. Small fiber neuropathy. Muscle Nerve 2202; 26: 173–188
   Google Scholar
• Argov Z, Siegal T. Leptomeningeal metastases: peripheral nerve and root involvement – clinical and electrophysiological study. Ann Neurol 1985; 17: 593–596
   PubMed Web of Science ®Google Scholar
• Notermans N C, Lokhorst H M, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996; 47: 1227–1233
   PubMed Web of Science ®Google Scholar
• Mariette X, Chastang C, Clavelou P, et al. A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997; 63: 28–34
   PubMed Web of Science ®Google Scholar
• Allen D, Lunn M P, Niermeijer J, et al. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007; CD005376
   PubMedGoogle Scholar
• Lunn M P, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006; CD002827
   PubMedGoogle Scholar
• Cook D, Dalakas M, Galdi A, et al. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40: 212–214
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Chevret S, Leger J M, et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1995; 59: 243–247
   PubMed Web of Science ®Google Scholar
• Wilson H C, Lunn M P, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999; 66: 575–580
   PubMed Web of Science ®Google Scholar
• Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999; 52: 1701–1704
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 485–489
   PubMed Web of Science ®Google Scholar
• Dalakas M C, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65: 286–293
   PubMed Web of Science ®Google Scholar
• Dyck P J, Low P A, Windebank A J, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325: 1482–1486
   PubMed Web of Science ®Google Scholar
• Gorson K C, Ropper A H, Weinberg D H, et al. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 2002; 59: 766–772
   PubMed Web of Science ®Google Scholar
• Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998; 51: S22–S24
   PubMedGoogle Scholar
• Rojas-Garcia R, Gallardo E, de Andres I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 2003; 61: 1814–1816
   PubMed Web of Science ®Google Scholar
• Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 2005; 32: 378–379
   PubMed Web of Science ®Google Scholar
• Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006; 66: 742–744
   PubMed Web of Science ®Google Scholar
• Zivkovic S A. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev Neurother 2006; 6: 1267–1274
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuropathy. Neurology 2008; 71: 1742–1744
   PubMed Web of Science ®Google Scholar
• Cheson B D, Leonard J P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613–626
   PubMed Web of Science ®Google Scholar
• Bonavita S, Conforti R, Russo A, et al. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurol Sci 2008; 29: 37–39
   PubMed Web of Science ®Google Scholar
• Lee Y C, Came N, Schwarer A, et al. Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplant 2002; 30: 53–56
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study. Arthritis Rheum 2006; 54: 3696–3706
   PubMed Web of Science ®Google Scholar
• Briani C, Chemello L, Zara G, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 2006; 67: 781–785
   PubMed Web of Science ®Google Scholar
• Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon α: a case report and literature review. Muscle Nerve 2002; 25: 909–913
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415–1418
   PubMed Web of Science ®Google Scholar
• Kyle R A, Remstein E D, Therneau T M, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582–2590
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M Q, Hayman S R, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 2008; 80: 397–406
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 2008; 71: 1691–1695
   PubMed Web of Science ®Google Scholar
• Vesole D H, Perez W S, Akasheh M, et al. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880–888
   PubMed Web of Science ®Google Scholar